BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid ...
Matinas Biopharma (NYSE: MTNB) stock jumped 313% yesterday then fell back 24%. MTNB stock raced ahead because their trial treatment seems to have actually cured a patient. This was not, though, as a ...
At first glance, the yeast Candida krusei seems as innocuous as microbes come: it's used for fermenting cocoa beans and gives chocolate its pleasant aroma. But it's increasingly being found as a ...
A major cause of drug-resistant clinical yeast infections is the same species previously regarded as non-pathogenic and commonly used in the biotechnology and food industries. A major cause of ...
Background: We have previously demonstrated efficacy against fungal colonization and infection of fluconazole prophylaxis that was routinely administered since 2001 in our ICU for preterm infants ...
This led to a dramatic improvement of clinical symptoms, allowing remobilization of the patient and her discharge on day +107 with rapidly decreasing inflammatory signs. Drug levels of voriconazole ...
Fibronectin (FN) is an abundant host protein that is specifically recognized by several pathogenic yeasts. Binding of FN in solution to Candida, Trichosporon, and Saccharomyces species is increased 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback